Highly Sensitive Lineage Discrimination of SARS-CoV-2 Variants through Allele-Specific Probe PCR.
Journal article
Ratcliff J. et al, (2022), Journal of clinical microbiology, e0228321 - e0228321
Divergent trajectories of antiviral memory after SARS-CoV-2 infection.
Journal article
Tomic A. et al, (2022), Nat Commun, 13
The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies.
Journal article
Spencer AJ. et al, (2022), EBioMedicine, 77
CMV-associated T cell and NK cell terminal differentiation does not impact immunogenicity of ChAdOx1 vaccination.
Journal article
Sharpe HR. et al, (2022), JCI Insight
Durability of ChAdOx1 nCov-19 vaccination in people living with HIV.
Journal article
Ogbe A. et al, (2022), JCI Insight
Efficacy of ChAdOx1 vaccines against SARS-CoV-2 Variants of Concern Beta, Delta and Omicron in the Syrian hamster model.
Journal article
van Doremalen N. et al, (2022), Res Sq
Response to Letter to the Editor by Ish et al. entitled 'COVID-19 vaccine equity-the need of the hour'.
Journal article
Maclean P. et al, (2022), QJM
Detection and Quantification of Antibody to SARS CoV 2 Receptor Binding Domain provides enhanced Sensitivity, Specificity and Utility.
Journal article
Rosadas C. et al, (2022), J Virol Methods
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Journal article
Costa Clemens SA. et al, (2022), Lancet
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Journal article
Dejnirattisai W. et al, (2022), Cell
Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection
Journal article
Feng S. et al, (2021), Nature Medicine
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.
Dejnirattisai W. et al, (2021)
Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-immunisation serum.
Journal article
Dejnirattisai W. et al, (2021), Lancet
Why do breakthrough COVID-19 infections occur in the vaccinated?
Journal article
Maclean P. et al, (2021), QJM
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Journal article
Clemens SAC. et al, (2021), Nature Communications, 12
ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7.
Journal article
Fischer RJ. et al, (2021), Nat Commun, 12
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil.
Journal article
Clemens SAC. et al, (2021), Nat Commun, 12